Skip to content

Study · Randomized controlled trial · n = 30 · 2018

9 results

Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.

Lambadiari V, Pavlidis G, Kousathana F, Varoudi M, Vlastos D, Maratou E, Georgiou D, Andreadou I, Parissis J, Triantafyllidi H, Lekakis J, Iliodromitis E, Dimitriadis G, Ikonomidis I

Cardiovascular diabetology8 Jan 2018Cited by 127 (Europe PMC)

PMID29310645 (opens in a new tab)PMCIDPMC5759220 (opens in a new tab)DOI10.1186/s12933-017-0646-z (opens in a new tab)PepBankPUB-29310645
Download PDFPubMedAsk about this study
Jump to 9 results

Summary

BackgroundIncretin-based therapies are used in the treatment of type 2 diabetes mellitus (T2DM) and obesity. We investigated the changes in arterial stiffness and left ventricular (LV) myocardial deformation after 6-month treatment with the GLP-1 analogue liraglutide in subjects with newly diagnosed T2DM.MethodsWe randomized 60 patients with newly diagnosed and treatment-naive T2DM to receive either liraglutide (n = 30) or metformin (n = 30) for 6 months. We measured at baseline and after 6-month treatment: (a) carotid-femoral pulse wave velocity (PWV) (b) LV longitudinal strain (GLS), and strain rate (GLSR), peak twisting (pTw), peak twisting velocity (pTwVel) and peak untwisting velocity (pUtwVel) using speckle tracking echocardiography. LV untwisting was calculated as the percentage difference between peak twisting and untwisting at MVO (%dpTw-UtwMVO), at peak (%dpTw-UtwPEF) and end of early LV diastolic filling (%dpTw-UtwEDF) (c) Flow mediated dilatation (FMD) of the brachial artery and percentage difference of FMD (FMD%) (d) malondialdehyde (MDA), protein carbonyls (PCs) and NT-proBNP.ResultsAfter 6-months treatment, subjects that received liraglutide presented with a reduced PWV (11.8 ± 2.5 vs. 10.3 ± 3.3 m/s), MDA (0.92 [0.45-2.45] vs. 0.68 [0.43-2.08] nM/L) and NT-proBNP (p < 0.05) in parallel with an increase in GLS (- 15.4 ± 3 vs. - 16.6 ± 2.7), GLSR (0.77 ± 0.2 vs. 0.89 ± 0.2), pUtwVel (- 97 ± 49 vs. - 112 ± 52°, p < 0.05), %dpTw-UtwMVO (31 ± 10 vs. 40 ± 14), %dpTw-UtwPEF (43 ± 19 vs. 53 ± 22) and FMD% (8.9 ± 3 vs. 13.2 ± 6, p < 0.01). There were no statistically significant differences of the measured markers in subjects that received metformin except for an improvement in FMD. In all subjects, PCs levels at baseline were negatively related to the difference of GLS (r = - 0.53) post-treatment and the difference of MDA was associated with the difference of PWV (r = 0.52) (p < 0.05 for all associations) after 6-month treatment.ConclusionsSix-month treatment with liraglutide improves arterial stiffness, LV myocardial strain, LV twisting and untwisting and NT-proBNP by reducing oxidative stress in subjects with newly diagnosed T2DM. ClinicalTrials.gov Identifier NCT03010683.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, 6 months of liraglutide reduced pulse wave velocity from baseline.

    In plain wordsIn adults with newly diagnosed type 2 diabetes, 6 months of liraglutide lowered arterial stiffness measured by pulse wave velocity.

    Peptide
    Liraglutide
    Outcome
    DecreaseCarotid-femoral pulse wave velocity
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    reduced PWV (11.8 ± 2.5 vs. 10.3 ± 3.3 m/s)
    1 context sentence
    Summary · context
    We randomized 60 patients with newly diagnosed and treatment-naive T2DM to receive either liraglutide (n = 30) or metformin (n = 30) for 6 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, 6 months of liraglutide reduced malondialdehyde from baseline.

    In plain wordsIn adults with newly diagnosed type 2 diabetes, 6 months of liraglutide lowered a blood marker of oxidative stress.

    Peptide
    Liraglutide
    Outcome
    DecreaseMalondialdehyde (oxidative stress marker)
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    MDA (0.92 [0.45-2.45] vs. 0.68 [0.43-2.08] nM/L)
    1 context sentence
    Summary · context
    We randomized 60 patients with newly diagnosed and treatment-naive T2DM to receive either liraglutide (n = 30) or metformin (n = 30) for 6 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, 6 months of liraglutide reduced NT-proBNP from baseline (p < 0.05).

    In plain wordsIn adults with newly diagnosed type 2 diabetes, 6 months of liraglutide lowered NT-proBNP, a heart strain marker.

    Peptide
    Liraglutide
    Outcome
    DecreaseNT-proBNP
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    and NT-proBNP (p < 0.05)
    1 context sentence
    Summary · context
    We randomized 60 patients with newly diagnosed and treatment-naive T2DM to receive either liraglutide (n = 30) or metformin (n = 30) for 6 months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, 6 months of liraglutide increased left ventricular global longitudinal strain from baseline.

    In plain wordsIn adults with newly diagnosed type 2 diabetes, 6 months of liraglutide improved a heart muscle strain measure.

    Peptide
    Liraglutide
    Outcome
    IncreaseLeft ventricular global longitudinal strain (GLS)
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    an increase in GLS (- 15.4 ± 3 vs. - 16.6 ± 2.7)
    1 context sentence
    Summary · context
    We randomized 60 patients with newly diagnosed and treatment-naive T2DM to receive either liraglutide (n = 30) or metformin (n = 30) for 6 months.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, 6 months of liraglutide increased global longitudinal strain rate from baseline.

    In plain wordsIn adults with newly diagnosed type 2 diabetes, 6 months of liraglutide improved a heart muscle strain rate measure.

    Peptide
    Liraglutide
    Outcome
    IncreaseGlobal longitudinal strain rate (GLSR)
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    GLSR (0.77 ± 0.2 vs. 0.89 ± 0.2)
    1 context sentence
    Summary · context
    We randomized 60 patients with newly diagnosed and treatment-naive T2DM to receive either liraglutide (n = 30) or metformin (n = 30) for 6 months.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, 6 months of liraglutide increased peak untwisting velocity from baseline (p < 0.05).

    In plain wordsIn adults with newly diagnosed type 2 diabetes, 6 months of liraglutide improved how fast the heart untwists.

    Peptide
    Liraglutide
    Outcome
    IncreasePeak untwisting velocity (pUtwVel)
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    pUtwVel (- 97 ± 49 vs. - 112 ± 52°, p < 0.05)
    1 context sentence
    Summary · context
    We randomized 60 patients with newly diagnosed and treatment-naive T2DM to receive either liraglutide (n = 30) or metformin (n = 30) for 6 months.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, 6 months of liraglutide increased left ventricular untwisting at mitral valve opening from baseline.

    In plain wordsIn adults with newly diagnosed type 2 diabetes, 6 months of liraglutide improved heart untwisting at the start of filling.

    Peptide
    Liraglutide
    Outcome
    IncreaseLV untwisting at mitral valve opening (%dpTw-Utw MVO)
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    %dpTw-UtwMVO (31 ± 10 vs. 40 ± 14)
    1 context sentence
    Summary · context
    We randomized 60 patients with newly diagnosed and treatment-naive T2DM to receive either liraglutide (n = 30) or metformin (n = 30) for 6 months.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, 6 months of liraglutide increased left ventricular untwisting at peak early filling from baseline.

    In plain wordsIn adults with newly diagnosed type 2 diabetes, 6 months of liraglutide improved heart untwisting at peak early filling.

    Peptide
    Liraglutide
    Outcome
    IncreaseLV untwisting at peak early filling (%dpTw-Utw PEF)
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    %dpTw-UtwPEF (43 ± 19 vs. 53 ± 22)
    1 context sentence
    Summary · context
    We randomized 60 patients with newly diagnosed and treatment-naive T2DM to receive either liraglutide (n = 30) or metformin (n = 30) for 6 months.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, brachial artery flow mediated dilatation increased from baseline after 6 months of liraglutide (p < 0.01); it also improved in the metformin group.

    In plain wordsIn adults with newly diagnosed type 2 diabetes, how well the arm artery widens improved after 6 months of liraglutide, and also with metformin.

    Peptide
    Liraglutide
    Outcome
    IncreaseFlow mediated dilatation percentage (FMD%)
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    FMD% (8.9 ± 3 vs. 13.2 ± 6, p < 0.01)
    2 context sentences
    Summary · context
    There were no statistically significant differences of the measured markers in subjects that received metformin except for an improvement in FMD.
    Summary · context
    We randomized 60 patients with newly diagnosed and treatment-naive T2DM to receive either liraglutide (n = 30) or metformin (n = 30) for 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 1 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2NCT05478707

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

AdventHealth Translational Research Instituten = 475 Oct 2023 to est. 30 Jul 2028

Diabetes Mellitus, Type 1 · Endothelial Dysfunction

Trial pageClinicalTrials.govUpdated 15 Oct 2026
Status unknownNot applicableNCT06611904

The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

Attikon Hospitaln = 601 Feb 2018 to est. 15 Dec 2024

Urine Albumin (UAlb) · Glycocalyx · Arterial Stiffness

Trial pageClinicalTrials.govUpdated 25 Sept 2024
CompletedNot applicableResults postedNCT03010683

Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus

University of Athensn = 60Nov 2015 to Dec 2017

Type 2 Diabetes Mellitus · Coronary Artery Disease

Trial pageClinicalTrials.govUpdated 5 Mar 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.